Sangamo Biosciences, Inc.  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
-0.10 (-0.63%)
Real-time:   12:10PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.64 - 16.18
52 week 9.39 - 19.25
Open 15.73
Vol / Avg. 171,247.00/925,871.00
Mkt cap 1.09B
P/E     -
Div/yield     -
EPS -0.40
Shares 69.06M
Beta 2.13
Inst. own 76%
May 4, 2015
Q1 2015 Sangamo BioSciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 25, 2015
Sangamo BioSciences Inc at Alliance for Regenerative Medicine RegenMed Investor Day
Mar 4, 2015
Sangamo BioSciences Inc at Cowen Health Care Conference
Feb 12, 2015
Sangamo BioSciences Inc at Leerink Global Healthcare Conference
Feb 10, 2015
Q4 2014 Sangamo BioSciences Inc Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Sangamo BioSciences Inc Earnings Release
Jan 12, 2015
Sangamo BioSciences Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -28.89% -57.59%
Operating margin -29.89% -58.38%
EBITD margin - -57.19%
Return on average assets -7.06% -13.76%
Return on average equity -8.31% -16.09%
Employees 102 -
CDP Score - -


501 Canal Blvd
RICHMOND, CA 94804-3559
United States - Map
+1-510-9706000 (Phone)
+1-510-2368951 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sangamo Biosciences, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the research, development and commercialization of engineered DNA-binding proteins for the development of therapeutic strategies for unmet medical needs. The Company�s mission is to develop ZFP Therapeutics, which is human therapeutics based on the Company�s ZFP technology through early stage clinical testing, strategically partner with biopharmaceutical companies at points of value inflection and have the partner execute late-stage clinical trials and commercial development. The Company�s lead ZFP Therapeutic, SB-728-T, ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is a therapeutic application of ZFN technology and is being evaluated in ongoing clinical trials, a Phase 2 study and a Phase 1/2 study in HIV-infected subjects.

Officers and directors

William R Ringo JR Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Edward O. Lanphier II President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
H. Ward Wolff Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Age: 65
Bio & Compensation  - Reuters
Geoffrey M. Nichol Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Philip D. Gregory Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 43
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 58
Bio & Compensation  - Reuters
Paul B. Cleveland Independent Director
Age: 57
Bio & Compensation  - Reuters
Stephen G. Dilly Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Larson Independent Director
Age: 75
Bio & Compensation  - Reuters